Answers are grounded in this paper and cite their sources.
Hormonal manipulation represents an attractive therapeutic approach to patients with symptomatic benign prostatic hyperplasia (BPH). Antiandrogenic therapies have been incompletely evaluated but appear to shrink the prostate by 30% to 40%. However, their effect on symptoms is uncertain. Antiestrogenic therapy is also theoretically possible, as estrogens may be synergistic with androgens in stimulating and maintaining prostatic growth. The physiologic rationale and the clinical data derived from evaluation of various forms of hormonal therapy for BPH are reviewed.
No takes yet. Share an insight, caveat, or question.
Gerald L. Andriole (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: